Rapt Therapeutics (NASDAQ:RAPT) Given Consensus Rating of “Hold” by Brokerages

Shares of Rapt Therapeutics (NASDAQ:RAPT) have received a consensus recommendation of “Hold” from the six brokerages that are presently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, three have issued a hold rating, one has assigned a buy rating and one has given a strong buy rating to the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $24.00.

A number of research analysts have recently issued reports on the company. UBS Group dropped their target price on Rapt Therapeutics from $16.00 to $8.00 and set a “neutral” rating on the stock in a report on Thursday, May 22nd. HC Wainwright raised shares of Rapt Therapeutics to a “strong-buy” rating and set a $48.00 price objective on the stock in a research note on Thursday, May 22nd. Finally, Wall Street Zen downgraded shares of Rapt Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, June 21st.

Rapt Therapeutics Stock Performance

Shares of NASDAQ:RAPT opened at $8.01 on Friday. Rapt Therapeutics has a one year low of $5.67 and a one year high of $30.60. The stock has a market capitalization of $132.49 million, a price-to-earnings ratio of -0.42 and a beta of -0.09. The company has a 50-day simple moving average of $7.73 and a 200-day simple moving average of $8.89.

Rapt Therapeutics (NASDAQ:RAPT) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.64) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.48) by $1.84. As a group, research analysts forecast that Rapt Therapeutics will post -2.14 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. TCG Crossover Management LLC acquired a new position in shares of Rapt Therapeutics during the 4th quarter worth $19,751,000. Orbimed Advisors LLC purchased a new stake in Rapt Therapeutics during the fourth quarter worth about $20,754,000. Foresite Capital Management VI LLC acquired a new position in Rapt Therapeutics during the fourth quarter worth about $19,750,000. RTW Investments LP purchased a new position in Rapt Therapeutics in the fourth quarter valued at about $18,587,000. Finally, BVF Inc. IL acquired a new stake in shares of Rapt Therapeutics during the 4th quarter valued at approximately $14,595,000. Hedge funds and other institutional investors own 99.09% of the company’s stock.

About Rapt Therapeutics

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.